MA50609B1 - Énantiomères de thiazoles substitués utilisés comme composés antiviraux - Google Patents

Énantiomères de thiazoles substitués utilisés comme composés antiviraux

Info

Publication number
MA50609B1
MA50609B1 MA50609A MA50609A MA50609B1 MA 50609 B1 MA50609 B1 MA 50609B1 MA 50609 A MA50609 A MA 50609A MA 50609 A MA50609 A MA 50609A MA 50609 B1 MA50609 B1 MA 50609B1
Authority
MA
Morocco
Prior art keywords
enantiomers
antiviral compounds
substituted thiazoles
thiazoles used
antiviral
Prior art date
Application number
MA50609A
Other languages
English (en)
Other versions
MA50609A (fr
Inventor
Christian Gege
Gerald Kleymann
Original Assignee
Innovative Molecules Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovative Molecules Gmbh filed Critical Innovative Molecules Gmbh
Publication of MA50609A publication Critical patent/MA50609A/fr
Publication of MA50609B1 publication Critical patent/MA50609B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La présente invention concerne de nouveaux composés antiviraux présentant une stéréoconfiguration spécifique, plus particulièrement de nouveaux énantiomères spécifiques, un procédé pour leur préparation et leur utilisation en tant que médicaments, en particulier en tant que médicaments antiviraux.
MA50609A 2017-10-05 2018-10-04 Énantiomères de thiazoles substitués utilisés comme composés antiviraux MA50609B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17195047 2017-10-05
PCT/EP2018/077022 WO2019068817A1 (fr) 2017-10-05 2018-10-04 Énantiomères de thiazoles substitués utilisés comme composés antiviraux

Publications (2)

Publication Number Publication Date
MA50609A MA50609A (fr) 2020-08-12
MA50609B1 true MA50609B1 (fr) 2023-03-31

Family

ID=60022026

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50609A MA50609B1 (fr) 2017-10-05 2018-10-04 Énantiomères de thiazoles substitués utilisés comme composés antiviraux

Country Status (36)

Country Link
US (2) US11278534B2 (fr)
EP (2) EP4209491A1 (fr)
JP (1) JP7215689B2 (fr)
KR (1) KR20200066619A (fr)
CN (1) CN111433203B (fr)
AR (1) AR113344A1 (fr)
AU (1) AU2018344471B2 (fr)
BR (1) BR112020006710A2 (fr)
CA (1) CA3077397A1 (fr)
CL (1) CL2020000869A1 (fr)
CR (1) CR20200154A (fr)
DK (1) DK3692039T3 (fr)
EA (1) EA202090620A1 (fr)
EC (1) ECSP20021132A (fr)
ES (1) ES2939652T3 (fr)
FI (1) FI3692039T3 (fr)
HR (1) HRP20230158T1 (fr)
HU (1) HUE061307T2 (fr)
IL (1) IL273681A (fr)
JO (1) JOP20200110A1 (fr)
LT (1) LT3692039T (fr)
MA (1) MA50609B1 (fr)
MD (1) MD3692039T2 (fr)
MX (1) MX2020003369A (fr)
NI (1) NI202000025A (fr)
PH (1) PH12020550132A1 (fr)
PL (1) PL3692039T3 (fr)
PT (1) PT3692039T (fr)
RS (1) RS64000B1 (fr)
SG (1) SG11202002420SA (fr)
SI (1) SI3692039T1 (fr)
TW (1) TWI706941B (fr)
UA (1) UA126163C2 (fr)
UY (1) UY37917A (fr)
WO (1) WO2019068817A1 (fr)
ZA (1) ZA202002150B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111433203B (zh) * 2017-10-05 2024-02-13 创新分子股份有限公司 作为抗病毒化合物的取代噻唑的对映异构体
WO2019168874A1 (fr) 2018-02-27 2019-09-06 The Research Foundation For The State University Of New York Compositions de difluorométhoxylation et de trifluorométhoxylation et leurs procédés de synthèse
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
JP2023552274A (ja) 2020-10-29 2023-12-15 イノベーティブ モレキュールズ ゲーエムベーハー 抗ウイルス化合物としての重水素化アミノチアゾール化合物
WO2023135303A1 (fr) 2022-01-17 2023-07-20 Innovative Molecules Gmbh Formes cristallines solides d'inhibiteurs d'hélicase-primase et leur procédé de préparation
WO2024049760A1 (fr) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. Composés de thiazolyl-urée cyclique pour le traitement du vhs
WO2024047508A1 (fr) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. Compositions pharmaceutiques contre le virus de l'herpès

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH564301A5 (fr) 1970-01-16 1975-07-31 Shell Int Research
WO1997024343A1 (fr) 1995-12-29 1997-07-10 Boehringer Ingelheim Pharmaceuticals, Inc. Derives de phenylthiazole dotes de proprietes anti virus de l'herpes
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
AU3289299A (en) 1998-02-19 1999-09-06 Tularik Inc. Antiviral agents
ATE229945T1 (de) 1998-03-19 2003-01-15 Upjohn Co Zur behandlung von cmv infektionen geeignete 1,3, 4-thiadiazole
DE19959958A1 (de) 1999-12-13 2001-08-30 Bayer Ag Thiazolylharnstoff-Derivate
US6500817B1 (en) 1999-03-08 2002-12-31 Bayer Aktiengesellschaft Thiazolyl urea derivatives and their utilization as antiviral agents
DE19927415A1 (de) 1999-06-16 2000-12-21 Bayer Ag Indolinylharnstoffderivate
DOP2000000109A (es) 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
DE10039265A1 (de) 2000-08-11 2002-02-21 Bayer Ag Thiazolylamid-Derivate
EP1319185A1 (fr) 2000-06-15 2003-06-18 Bayer Aktiengesellschaft Methodes d'identification de composes presentant une activite antiherpes
DE10038022A1 (de) 2000-08-04 2002-02-14 Bayer Ag Inverse Thiazolylamid-Derivate
DE10044358A1 (de) 2000-09-07 2002-03-21 Bayer Ag Thiazolylcarbonylheterocyclyl-Derivate
DE10044328A1 (de) 2000-09-07 2002-03-21 Bayer Ag Thiazolylcarbonyl-Derivate
DE10044353A1 (de) 2000-09-07 2002-04-04 Bayer Ag Unkompetitive Inhibitoren der Helikase-Primase
DE10129717A1 (de) 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10129714A1 (de) 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
DE10129715A1 (de) 2001-06-22 2003-01-02 Bayer Ag Thiazolylamide
DE10129716A1 (de) 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10131128A1 (de) 2001-06-28 2003-01-16 Bayer Ag Sekundäre Sulfonamide
DE10210319A1 (de) 2002-03-08 2003-09-18 Bayer Ag Thiazolylcarbonyl-Derivate
DE10235967B4 (de) 2002-08-06 2005-09-08 Bayer Healthcare Ag Methode zum Identifizieren von Substanzen mit antimikrobieller Wirkung
DE10300109A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Methode zur Inhibition der Replikation von Herpesviren
AU2005210474B2 (en) 2004-01-30 2011-07-07 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding cassette transporters
DE102005014248A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
US8548554B2 (en) 2006-12-08 2013-10-01 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Dry electrode cap for electro-encephalography
DE102010046720A1 (de) 2010-09-23 2012-03-29 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von pan-CDK-Inhibitoren der Formel (l), sowie Intermediate der Herstellung
JP5837936B2 (ja) * 2010-11-01 2015-12-24 ロマーク ラボラトリース，エル．シー． アルキルスルフィニル置換チアゾリド化合物
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
EP2573086A1 (fr) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG Monohydrate de mesylate acétamide N-[5-(Aminosulfonyl)-4-méthyl-1,3-thiazol-2-yl]-N-méthyl-2-[4-(2-pyridinyl)phényl]
EP3440063B1 (fr) * 2016-04-06 2020-08-05 Innovative Molecules GmbH Dérivés aminothiazoles en tant qu'agents antiviraux
CN110062755B (zh) 2016-11-28 2023-08-29 艾库里斯有限及两合公司 普瑞利韦的游离碱的马来酸盐、其药物制剂、其制造方法及其用于治疗疱疹病毒的用途
AR110250A1 (es) 2016-11-28 2019-03-13 Aicuris Anti Infective Cures Gmbh Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida
RS61905B1 (sr) 2016-11-28 2021-06-30 Aicuris Gmbh & Co Kg Hemihidrat slobodne baze n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida, postupci njegove proizvodnje i upotrebe
CN110225781B (zh) 2017-01-09 2022-05-17 辉诺生物医药科技（杭州）有限公司 噻唑衍生物及其应用
CN111433203B (zh) * 2017-10-05 2024-02-13 创新分子股份有限公司 作为抗病毒化合物的取代噻唑的对映异构体

Also Published As

Publication number Publication date
AU2018344471A1 (en) 2020-04-09
AU2018344471B2 (en) 2022-09-29
PT3692039T (pt) 2023-03-07
HUE061307T2 (hu) 2023-06-28
ES2939652T3 (es) 2023-04-25
TWI706941B (zh) 2020-10-11
PH12020550132A1 (en) 2021-02-08
CN111433203A (zh) 2020-07-17
AR113344A1 (es) 2020-04-22
SG11202002420SA (en) 2020-04-29
NI202000025A (es) 2020-07-31
HRP20230158T1 (hr) 2023-03-31
JOP20200110A1 (ar) 2020-05-07
UY37917A (es) 2019-04-30
BR112020006710A2 (pt) 2022-11-08
WO2019068817A1 (fr) 2019-04-11
US20200289486A1 (en) 2020-09-17
RS64000B1 (sr) 2023-03-31
CR20200154A (es) 2020-05-24
KR20200066619A (ko) 2020-06-10
EP3692039B1 (fr) 2022-12-14
CL2020000869A1 (es) 2020-09-21
MX2020003369A (es) 2020-07-29
EP4209491A1 (fr) 2023-07-12
JP2020536108A (ja) 2020-12-10
ZA202002150B (en) 2022-10-26
SI3692039T1 (sl) 2023-04-28
US20220152008A1 (en) 2022-05-19
PL3692039T3 (pl) 2023-04-17
IL273681A (en) 2020-05-31
TW201927758A (zh) 2019-07-16
DK3692039T3 (da) 2023-03-13
LT3692039T (lt) 2023-03-27
UA126163C2 (uk) 2022-08-25
MA50609A (fr) 2020-08-12
CN111433203B (zh) 2024-02-13
FI3692039T3 (fi) 2023-03-23
CA3077397A1 (fr) 2019-04-11
EP3692039A1 (fr) 2020-08-12
US11278534B2 (en) 2022-03-22
ECSP20021132A (es) 2020-07-31
JP7215689B2 (ja) 2023-01-31
MD3692039T2 (ro) 2023-05-31
EA202090620A1 (ru) 2020-07-10

Similar Documents

Publication Publication Date Title
MA50609B1 (fr) Énantiomères de thiazoles substitués utilisés comme composés antiviraux
MA46325B1 (fr) Composés dinucléotidiques cycliques
MA49809A1 (fr) Composés utilisés comme inhibiteurs de kinase
CA3010752A1 (fr) Inhibiteurs de l'interaction proteine/proteine pd-1/pd-l1
CU20180073A7 (es) Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen
BR112022007163A2 (pt) Heterociclos bicíclicos como inibidores de fgfr
MX2022016427A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
MA46531A (fr) Dérivés d'azétidine ou de cyclobutane 1,3-disubstitués utilisés comme inhibiteurs de la prostaglandine d synthase hématopoïétique (h-pgds)
BR112018071511A2 (pt) polímeros à base de etileno e processos para fazer os mesmos
FR3068979B1 (fr) Composition d'adhesif (meth)acrylique, son procede de preparation et son utilisation
BR112017017349A2 (pt) composto, composição, método para tratar um distúrbio
MA40895A (fr) Synthèse de copanlisib et son sel de dichlorhydrate
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
CO6321288A2 (es) Sales de compuestos inhibidores de vih
PE20221420A1 (es) Procedimiento fotoquimico para la preparacion de (4r,4s)-4-(4-ciano-2-metoxifenil)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-carboxamida
FR3064634B1 (fr) Derives acryliques de 1 :4, 3 :6 dianhydrohexitol
MA50895A (fr) Nouveaux composés biaryles substitués utilisés en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido)
MA39337B1 (fr) Modulateurs de pyrazines de gpr6
MA39387A1 (fr) Colorants réactifs fluorescents, procédé de production et utilisation de ceux-ci
MA39190A1 (fr) Dérivés d'imidazolyle fusionnés, leur préparation et leur utilisation en tant que médicaments
MA43250B1 (fr) Composés d'oxadiazaspiro pour le traitement de l'abus et la dépendance aux drogues
FR3062851B1 (fr) Procede de preparation monotope de composes organo-iodes
FR3068980B1 (fr) Composition d'adhesif epoxy comprenant un polymere a etapes multiples et un polymere (meth)acrylique, son procede de preparation et son utilisation
MA43158B1 (fr) Composés oxa-diazadispiro possédant une activité contre la douleur